Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Breast Cancer: early-phase trial registry
423 of 1,251 indexed Breast Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1 of 28,707 conditions by registered trial count.
1,251 US clinical trials · 423 currently recruiting · #1 of 28,707 conditions by registered trial count
Breast Cancer: 1,251 US clinical trials tracked, 423 recruiting.
Breast Cancer is the subject of 1,251 registered US clinical trials on ClinicalTrials.gov, 423 of them currently open to new participants. 120 are in Phase 3-4 (later-stage) and 491 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 98 of these trials.
Enrollment posture brief
Registry condition breast-cancer
OPEN 423 | RECR 34% | LATE 120 | EARLY 491 | RANK #1 | SPON 98
Volume-matched condition peers
Nearest open-share peer: Refractory Multiple Myeloma (34% recruiting · 68 trials)
Breast Cancer lists 423 open slots (34% of 1,251 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Breast Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Breast Cancer is recruiting below its size-band peers.
423 of 1,251 indexed trials (33.8%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Breast Cancer trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 98 of 1,251 trials (7.8%). 367 distinct sponsors appear on at least one study for this condition label.
-
Typical Breast Cancer enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,225 trials that report a genuine target (sentinel values excluded). 630 of those (51.4%) plan for fewer than 100 participants.
-
Breast Cancer research is mostly interventional.
1,015 interventional and 236 observational studies make up this index (81.1% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,251 total, page 13 of 26
Omega 3 Fatty Acids and ERPR(-)HER2(+/-) Breast Cancer Prevention
City of Hope Medical Center
NCT02295059
ZAP-IT: ZN-c3 + Carboplatin + Pembrolizumab in mTNBC
Filipa Lynce, MD
NCT06351332
A Study of DS-1103a Combination Therapy in Participants With Advanced Solid Tumors
Daiichi Sankyo
NCT05765851
Use of Sentinel Lymph Node Biopsy in Patients With Early-Stage, Palpable Node-Positive HR+/HER2- Breast Cancer Having Upfront Surgery and Adjuvant Radiation
Memorial Sloan Kettering Cancer Center
NCT04854005
Carboplatin +/- Nivolumab in Metastatic Triple Negative Breast Cancer
Dana-Farber Cancer Institute
NCT03414684
AKT Inhibitor, Ipatasertib, With Endocrine and CDK 4/6 Inhibitor for Patients With Metastatic Breast Cancer (TAKTIC)
Massachusetts General Hospital
NCT03959891
Three Fraction Accelerated Partial Breast Irradiation as the Sole Method of Radiation Therapy for Low-risk Stage 0 and I Breast Carcinoma
Washington University School of Medicine
NCT03612648
Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
Massachusetts General Hospital
NCT04039230
Phase II Multi-center Trial Evaluating 5 Fraction Stereotactic Partial Breast Irradiation Using Gammapod
University of Texas Southwestern Medical Center
NCT03581136
A Study to Learn About Vepdegestrant When Given With PF-07220060 to People With Advanced or Metastatic Breast Cancer.
Pfizer
NCT06206837
Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors
NGM Biopharmaceuticals
NCT05311618
Phase II Study of Pembrolizumab and Nab-paclitaxel in HER-2 Negative Metastatic Breast Cancer
NYU Langone Health
NCT02752685
Searching for Masses and Calcifications at the Same Time in Breast Cancer Screening
Brigham and Women's Hospital
NCT05975736
Carboplatin and Nab-Paclitaxel With or Without Vorinostat in Treating Women With Newly Diagnosed Operable Breast Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00616967
Study of the Safety of MRI Scans in People Who Have Breast Tissue Expanders After Mastectomy
Memorial Sloan Kettering Cancer Center
NCT04769960
Moving Forward Together 4
University of South Carolina
NCT05409664
Breast Cancer Study of Preoperative Pembrolizumab + Radiation
Stephen Shiao
NCT03366844
Niraparib + Dostarlimab In BRCA Mutated Breast Cancer
Dana-Farber Cancer Institute
NCT04584255
Preoperative Fulvestrant With or Without Enzalutamide in ER+/Her2- Breast Cancer
University of Colorado, Denver
NCT02955394
Rehabilitation of Cognitive Changes in Breast Cancer Survivors
Memorial Sloan Kettering Cancer Center
NCT01182506
Prospective Study of the Prosigna Assay on Neoadjuvant Clinical Decision-making in Women With HR+/Her2- Breast Cancer
Dana-Farber Cancer Institute
NCT03749421
Physical Activity, Proliferation and Immune Markers in Benign Breast Tissue
Dana-Farber Cancer Institute
NCT03657628
Psychosexual Educational Partners Program (PEPP)
The University of Tennessee, Knoxville
NCT06253182
Ultrahypofractionation and Normal Tissue Toxicity
Massachusetts General Hospital
NCT05912231
Vepdegestrant (ARV-471/PF-07850327) + Palbociclib vs Letrozole + Palbociclib in ER(+)/HER2(-) Advanced Breast Cancer
Pfizer
NCT05909397
Hypofractionated Regional Nodal Irradiation in Breast Cancer
Corewell Health East
NCT06443359
Part II: Exercise in Hispanic Breast Cancer Survivors
M.D. Anderson Cancer Center
NCT01504789
Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)
Priyanka Sharma
NCT02393794
Clinical Trial Assessing the Safety of Neoadjuvant Palbociclib in Combination With Endocrine Therapy
University of Nebraska
NCT05069038
Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
University of Pennsylvania
NCT03846167
Heart Health After Cancer Treatment (HEART-ACT)
University of California, San Francisco
NCT06055803
Onvansertib + Paclitaxel In TNBC
Antonio Giordano, MD
NCT05383196
Feasibility Study of Adjuvant Enzalutamide for the Treatment of Early Stage AR (+) Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT02750358
Study of Neoadjuvant Olaparib Monotherapy and Olaparib and Durvalumab Combination in HER2 Negative BRCAm Breast Cancer
AstraZeneca
NCT05498155
The Preoperative Health & Body Study
Dana-Farber Cancer Institute
NCT01516190
Brain Functional MRI in Older Women With Breast Cancer (Brain fMRI-BC)
City of Hope Medical Center
NCT01992432
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
University of Pittsburgh
NCT05914792
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Carisma Therapeutics
NCT04660929
Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer Patients
Nancy Chan, MD
NCT03393845
A Study of the Use of Text Message Reminders to Take Palbociclib
Memorial Sloan Kettering Cancer Center
NCT04216576
Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT03439735
A Phase I Dose Escalation Study of Single Fraction Pre-operative Partial Breast (S-PBI) for Early Stage Breast Cancer
University of Texas Southwestern Medical Center
NCT04040569
CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer
Treadwell Therapeutics
NCT05251714
A Study of Flibanserin in Breast Cancer Survivors on Tamoxifen or Aromatase Inhibitors
Memorial Sloan Kettering Cancer Center
NCT03707340
Assessment of Paclitaxel-Induced Neuropathy
University of Chicago
NCT01953159
Feasibility and Identification of Breast Cancer Patients for Potential Avoidance of Surgery
M.D. Anderson Cancer Center
NCT02455791
A Study of the Body's Response to Exercise and a Plant-Based Diet in Overweight Postmenopausal Women With Breast Cancer
Memorial Sloan Kettering Cancer Center
NCT04298086
Exercise, Fitness and Tumor Profiling in Breast Cancer Patients
Memorial Sloan Kettering Cancer Center
NCT03424915
Curcumin in Reducing Joint Pain in Breast Cancer Survivors With Aromatase Inhibitor-Induced Joint Disease
City of Hope Medical Center
NCT03865992
'ADVANCE' (A Pilot Trial)
Dana-Farber Cancer Institute
NCT03858322
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 235 |
| Phase 2 | 256 |
| Phase 3 | 100 |
| Phase 4 | 20 |
Top Sponsors
Named interventions
Most-linked intervention names on Breast Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Breast Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Breast Cancer page
1,251 registered trials, 423 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 423 Breast Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Breast Cancer trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Breast Cancer condition card totals 1,251 registered trials; most-linked intervention Fulvestrant; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.